Navigation Links
Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
Date:3/17/2009

BALTIMORE, March 17 /PRNewswire/ -- Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate. "Our most recent Phase IIb study, the largest trial with an investigational medication conducted in patients with celiac disease, was a randomized, double-blind, placebo controlled, dose ranging, multicenter study to determine the safety, tolerance and efficacy of larazotide acetate in 184 adults with controlled celiac disease during a gluten challenge. The data are promising and will be publicly presented at upcoming scientific meetings this spring," said Bruce Peacock, CEO of Alba Therapeutics. "Recently, Alba restructured to concentrate its efforts on advancing the clinical program for larazotide acetate, and we are now moving forward with initiating our next clinical trial in patients with celiac disease."

Additionally, Alba announced that Francisco Leon, MD, PhD has been promoted to Vice President and Chief Medical Officer. "I am very pleased to have Dr. Leon assume the responsibilities of CMO. His passion for developing a treatment for celiac disease is an inspiration to all Alba employees." Alba also announced that Dr. Linda Arterburn has been promoted to Vice President of Development. "Our team consists of a fine, talented group of people who are dedicated to help us meet the unmet medical needs of patients with celiac disease and other autoimmune and inflammatory diseases," said Bruce Peacock.

Francisco Leon, MD, PhD, formerly Vice President, Clinical Operations and Medical Affairs, has been promoted to Vice President and Chief Medical Officer. Dr. Leon is an immunologist with broad training in basic and clinical Immunology and a vocation for clinical development in the field of Mucosal Immunology. Prior to joining Alba in September 2007, Dr. Leon was a Director of Clinical Development, Inf
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
2. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
3. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
4. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
5. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
6. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
7. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
10. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
11. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... 2 Cardinal Health today...ny,s board of directors, effective immediately. ,...e president and president of global pharmaceutical...e with the company at the close of its merger with...ering-Plough, Cox served as president of Pharmacia...
(Date:12/2/2009)...ND, Sweden, December 2 DermaGen AB...and wound healing company "Pergamum" -,today annou...ts from a,clinical Phase I/IIa study. DermaGen AB ...treatment for atopic dermatitis. Atopic dermatitis...skin and the skin,s weakened barrier,function make...
(Date:12/2/2009)...sreal, December 2 Cardio...g developer of advanced,cardiovascular surgery tec...of Directors approved a one-for-three forward stoc...to Cardio Vascular Medical Device shareholders. ,...he estimated date the stock,split will be payable ...
Breaking Medicine Technology:Cardinal Health Names Carrie Cox to Board of Directors 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4Cardio Vascular Medical Device Announces Forward Stock Split 2Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30 28th 29 Anniversary Gala During First Visit to Long Island 47945 1Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30 28th 29 Anniversary Gala During First Visit to Long Island 47945 2Advances in Medical Technology Identified as a Primary Driver of Increased Costs 47943 1Advances in Medical Technology Identified as a Primary Driver of Increased Costs 47943 2Advances in Medical Technology Identified as a Primary Driver of Increased Costs 47943 3Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 1Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 2Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 3
... Nov. 3 Mpex Pharmaceuticals, Inc. today,announce...ith MP-376 for,use as a maintenance therapy in red...patients with chronic obstructive pulmonary diseas...n of levofloxacin,inhalation solution., The Phase...cebo-controlled study (Mpex 302) is expected to en...
...percent of patients achieve undetectable viral loa...eatment with standard of care, SAN FRANCISCO, Nov...TMC435, an investigational protease inhibitor (PI)... of chronic hepatitis C virus,(HCV) infection. Tib...es,including a late-breaker poster on the proof-of...
Other Medicine Technology:Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 2Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5
(Date:12/2/2009)... A team of Kendall Hunt authors earned the 2... at the recent National Association for Gifted Chi...mber 5-7, 2009. , Dubuque... Hunt authors earned the 2009 Gifted Child Quarter...Association for Gifted Children’s annual con...
(Date:12/2/2009)... Today,s Washington Post Highlights Dangers ...-- If the Catholic bishops have their way, many...ake for granted may be under threat. The pressure...ebate over healthcare reform has been widely repor...ns of the likely impact if that pressure to influe...
(Date:12/2/2009)...uspected in birth defect that affects male urethra...(HealthDay News) -- Male babies of women who use i...pregnancy appear to be at increased risk for a bir..., This birth defect, which affects about two of...ning of the urethra, the tube that carries urine f...
(Date:12/2/2009)... seem like unlikely heroes in the battle against d...sects already used to study dozens of human disea...g that fruit flies can be used as a simpler and mo...s of cocaine and other drugs of abuse on the brain...oscience , a new monthly journal. , Andrew Ewin...
(Date:12/2/2009)... MyCareTeam, Inc., a leading vendor of Inter... released the newest version of its software offer...ongestive heart failure and weight management capa...toring features. , Acto...., a leading vendor of Internet-based chronic dise...
Breaking Medicine News(10 mins):Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure 2
...are shedding light on a rare form of early blindne...way for possible therapies// to treat or even prev...The findings, funded by Fight for Sight and the Na...nce his post-doctoral days at Harvard University, ...
...o your pizza or spaghetti, make sure it’s made fro... Scientists from Ohio State University have report...nown antioxidant found in tomatoes, is absorbed be.... Lycopene is said to be a potent antioxidan...
...racic cancer, reportedly the countries number one ...ed// to have specialist comprising of radiation on...estigators. These experts are flying in from Unite...c cancers from around the globe. Several papers wi...
...rican women found that most of them had insufficie...nd physical health// , personal lives, professiona...rvey sponsored by the National Sleep Foundation, s...p each week, and 40 percent have disturbed sleep e...
...ch researchers suggest that the hormone glucocorti... be//. The steroid is prescribed by many specialis... The steroid hormones called glucocorticoids...o sensitize the lining of the uterus so that embry...
...sity finds that women on the Atkins low-carbohydra...ar diets//. It also found that their blood pressur... On average, women taking the Atkins diet lost 1... those following the Zone weight-loss plan. ...
Other Medicine News:Health News:Biologists Trace Cause Of Early Blindness To Tissue Defect 2Health News:Biologists Trace Cause Of Early Blindness To Tissue Defect 3Health News:Pass the Orange Tomato Sauce Please 2Health News:Sleep Problems of Women 2Health News:Atkin’s Low-carb Diet Best for Weight Los 2
Gigli (Olivecrona) Wire Saws
Galt Skull Trephine
Cone Skull Punch
Greenberg Pattie Tray
Medicine Products: